Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,135.95
(
-0.04%
)
US TECH 100
26,674.80
(
1.42%
)
Dow Jones
48,861.81
(
-0.57%
)
Brent Oil
113.49
(
0.99%
)
Bitcoin
75,598.93
(
-0.23%
)
News Focus
News Focus
Post# of 257470
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122909
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 06/24/2024 2:21:04 PM

Monday, June 24, 2024 2:21:04 PM

Post# of 257470
ANIP acquires ALIM for $5.50/sh cash—a 75% premium to Friday’s close:

https://www.globenewswire.com/news-release/2024/06/24/2902835/0/en/ANI-Pharmaceuticals-to-Further-Expand-Rare-Disease-Business-through-Acquisition-of-Alimera-Sciences.html

The consideration includes a non-tradable CVR worth up to $0.50/sh. The nominal deal value (excluding the CVR) is $381M.

ALIM markets the Iluvien and Yutiq implants for DME and posterior uveitis, respectively. ALIM bought Yutiq from EYPT in May 2023 (https://investors.eyepointpharma.com/news-releases/news-release-details/eyepoint-pharmaceuticals-announces-sale-yutiqr-alimera-sciences ).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today